Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Common Equity (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 16 years of Common Equity data on record, last reported at -$108.6 million in Q3 2025.

  • For Q3 2025, Common Equity fell 35.61% year-over-year to -$108.6 million; the TTM value through Sep 2025 reached -$108.6 million, down 35.61%, while the annual FY2024 figure was -$94.5 million, 43.66% down from the prior year.
  • Common Equity reached -$108.6 million in Q3 2025 per NWBO's latest filing, down from -$100.4 million in the prior quarter.
  • Across five years, Common Equity topped out at -$56.0 million in Q1 2023 and bottomed at -$353.2 million in Q1 2021.
  • Average Common Equity over 5 years is -$129.7 million, with a median of -$99.5 million recorded in 2025.
  • Peak YoY movement for Common Equity: plummeted 865.55% in 2021, then surged 73.8% in 2022.
  • A 5-year view of Common Equity shows it stood at -$124.0 million in 2021, then fell by 3.32% to -$128.1 million in 2022, then skyrocketed by 48.66% to -$65.8 million in 2023, then crashed by 43.66% to -$94.5 million in 2024, then dropped by 14.99% to -$108.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were -$108.6 million in Q3 2025, -$100.4 million in Q2 2025, and -$99.5 million in Q1 2025.